KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Common Equity (2016 - 2025)

Regeneron Pharmaceuticals has reported Common Equity over the past 17 years, most recently at $31.3 billion for Q4 2025.

  • Quarterly results put Common Equity at $31.3 billion for Q4 2025, up 6.48% from a year ago — trailing twelve months through Dec 2025 was $31.3 billion (up 6.48% YoY), and the annual figure for FY2025 was $31.3 billion, up 6.48%.
  • Common Equity for Q4 2025 was $31.3 billion at Regeneron Pharmaceuticals, up from $31.0 billion in the prior quarter.
  • Over the last five years, Common Equity for REGN hit a ceiling of $31.3 billion in Q4 2025 and a floor of $12.0 billion in Q1 2021.
  • Median Common Equity over the past 5 years was $24.5 billion (2023), compared with a mean of $24.1 billion.
  • Peak annual rise in Common Equity hit 70.44% in 2021, while the deepest fall reached 1.29% in 2021.
  • Regeneron Pharmaceuticals' Common Equity stood at $18.8 billion in 2021, then increased by 20.75% to $22.7 billion in 2022, then rose by 14.6% to $26.0 billion in 2023, then increased by 13.02% to $29.4 billion in 2024, then increased by 6.48% to $31.3 billion in 2025.
  • The last three reported values for Common Equity were $31.3 billion (Q4 2025), $31.0 billion (Q3 2025), and $29.9 billion (Q2 2025) per Business Quant data.